Your browser doesn't support javascript.
loading
Can Australia Reach the World Health Organization Hepatitis C Elimination Goal by 2025 Among Human Immunodeficiency Virus-positive Gay and Bisexual Men?
Boettiger, David C; Salazar-Vizcaya, Luisa; Dore, Gregory J; Gray, Richard T; Law, Matthew G; Callander, Denton; Lea, Toby; Rauch, Andri; Matthews, Gail V.
Afiliação
  • Boettiger DC; Kirby Institute, University of New South Wales Sydney, Australia.
  • Salazar-Vizcaya L; Department of Infectious Diseases, Bern University Hospital, University of Bern, Inselpital, Switzerland.
  • Dore GJ; Kirby Institute, University of New South Wales Sydney, Australia.
  • Gray RT; Kirby Institute, University of New South Wales Sydney, Australia.
  • Law MG; Kirby Institute, University of New South Wales Sydney, Australia.
  • Callander D; Kirby Institute, University of New South Wales Sydney, Australia.
  • Lea T; Centre for Social Research in Health, University of New South Wales Sydney, Australia.
  • Rauch A; German Institute for Addiction and Prevention Research, Catholic University of Applied Sciences, Cologne.
  • Matthews GV; Department of Infectious Diseases, Bern University Hospital, University of Bern, Inselpital, Switzerland.
Clin Infect Dis ; 70(1): 106-113, 2020 01 01.
Article em En | MEDLINE | ID: mdl-30816916
ABSTRACT

BACKGROUND:

Human immunodeficiency virus (HIV)-positive gay and bisexual men (GBM) in Australia are well engaged in care. The World Health Organization's (WHO) hepatitis C virus (HCV) elimination target of an 80% reduction in incidence by 2030 may be reachable ahead of time in this population.

METHODS:

We predicted the effect of treatment and behavioral changes on HCV incidence among HIV-positive GBM up to 2025 using a HCV transmission model parameterized with Australian data. We assessed the impact of changes in behavior that facilitate HCV transmission in the context of different rates of direct-acting antiviral (DAA) use.

RESULTS:

HCV incidence in our model increased from 0.7 per 100 person-years in 2000 to 2.5 per 100 person-years in 2016 and had the same trajectory as previously reported clinical data. If the proportion of eligible (HCV RNA positive) patients using DAAs stays at 65% per year between 2016 and 2025, with high-risk sexual behavior and injecting drug use remaining at current levels, HCV incidence would drop to 0.4 per 100 person-years (85% decline from 2016). In the same treatment scenario but with substantial increases in risk behavior, HCV incidence would drop to 0.6 per 100 person-years (76% decline). If the proportion of eligible patients using DAAs dropped from 65% per year in 2016 to 20% per year in 2025 and risk behavior did not change, HCV incidence would drop to 0.7 per 100 person-years (70% reduction).

CONCLUSIONS:

Reaching the WHO HCV elimination target by 2025 among HIV-positive GBM in Australia is achievable.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Infecções por HIV / Hepatite C / Hepatite C Crônica / Minorias Sexuais e de Gênero Tipo de estudo: Incidence_studies / Prognostic_studies Limite: Humans / Male País/Região como assunto: Oceania Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Infecções por HIV / Hepatite C / Hepatite C Crônica / Minorias Sexuais e de Gênero Tipo de estudo: Incidence_studies / Prognostic_studies Limite: Humans / Male País/Região como assunto: Oceania Idioma: En Revista: Clin Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Austrália